Spending on DTC advertising on the rise

Author：

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.351, 2002-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Arguments for and against DTC advertising

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 359, 2002-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

DTC advertising wasteful and misleading

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 435, 2003-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

In the year to March 2002, spending on direct-to-consumer (DTC) advertising for a single product in the US was highest for AstraZeneca's esomeprazole [`Nexium'] at $US177 million

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 398, 2003-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

DTC advertising vetoed, drug price cuts in Lithuania

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 367, 2002-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

DTC advertising of medical devices gains attention

Inpharma, Vol. 1, Iss. 1667, 2008-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite